Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 103

Sort by

Sort Order Select

Journal Articles

Preclinical and First-in-Human Phase I Study of Bruton Tyrosine Kinase Degrader HZ-Q1070 in Patients with Recurrent or Refractory B-Cell Malignancies

Yuqin Song, Ningjing Lin, Xingguo Liu, Yubo Zhou, Yizhe Wu, Xiaomin Luo, Jiangfeng Xie, Xinna Ma, Miao Hu, Yanping Zhang, Jia Li, Xinglu Zhou

Blood (2024) 144 (Supplement 1): 6286.

https://doi.org/10.1182/blood-2024-200544

Published: 2024

Journal Articles

Safety and Efficacy of Rocbrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma

Blood (2024) 144 (Supplement 1): 1635.

https://doi.org/10.1182/blood-2024-194572

Published: 2024

Journal Articles

SKYGLO: A Global Phase III Randomized Study Evaluating Glofitamab Plus Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Pola-R-CHP in Previously Untreated Patients with Large B-Cell Lymphoma (LBCL)

Ranjana H. Advani, Michael J. Dickinson, Christopher P. Fox, Brad Kahl, Alex F. Herrera, Georg Lenz, Yuqin Song, Rong Tao, Qingqing Cai, Tae Min Kim, Michelle Doral, Derrick Kaufman, Leonardo Roque Pereira, Aurelien Berthier, Franck Morschhauser

Blood (2024) 144 (Supplement 1): 1718.1.

https://doi.org/10.1182/blood-2024-194000

Published: 2024

Journal Articles

Molecular Biology Study of Primary Immuno-Privileged Lymphomas

Chen Zhang, Jili Deng, Lan Mi, Jiayue Qin, Lixia Liu, Yuqin Song

Blood (2024) 144 (Supplement 1): 4455.

https://doi.org/10.1182/blood-2024-212058

Published: 2024

Journal Articles

Prognosis Prediction and Treatment Recommendation for Follicular Lymphoma: Enhancing Decision-Making

Xinze Li, Jiaxin Liu, Lan Mi, Liantao Ma, Junyi Gao, Yan Xie, Yuqin Song

Blood (2024) 144 (Supplement 1): 6353.

https://doi.org/10.1182/blood-2024-212407

Published: 2024

Journal Articles

Linperlisib Combined with CHOP Regimen Followed By Autologous Hematopoietic Stem Cell Transplantation and Linperlisib Monotherapy Maintenance for Newly Diagnosed Nodal T-Follicular Helper Cell Lymphoma Patients: A Phase II Trial

Weiping Liu, Yao Liu, Zengjun Li, Shujuan Wen, Zhihua Zhang, Liqun Zou, Ming Jiang, Liping Dou, Ou Bai, Jie Yu, Yue Wang, Jie Chen, Yuqin Song, Jun Zhu

Blood (2024) 144 (Supplement 1): 6389.

https://doi.org/10.1182/blood-2024-199929

Published: 2024

Journal Articles

Safety and Efficacy of Iruplinalkib for Patients with Relapsed or Refractory (r/r) ALK+ Lymphoma: A Phase II Trial

Yue Wang, Fang Wei, Wanli Wang, Linjun Zhao, Jie Chen, Yuqin Song, Jun Zhu, Weiping Liu

Blood (2024) 144 (Supplement 1): 6386.

https://doi.org/10.1182/blood-2024-207002

Published: 2024

Journal Articles

MBS303, a Novel 2:1 CD20×CD3 Bispecific Antibody, Demonstrated a Favorable Safety and Potent Antitumor Activity in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma: Preliminary Results from a Phase Ⅰ, Dose-Escalation Trial

Yuqin Song, Haiyan Yang, Youchao Jia, Lixia Sheng, Lijuan Deng, Xi Chen, Yongjing Tang, Xifang Liu, Sijun Liu, Min Wei, Feng Li

Blood (2024) 144 (Supplement 1): 6481.

https://doi.org/10.1182/blood-2024-199342

Published: 2024

Journal Articles

BR105 Is a Novel Anti-Sirpα Monoclonal Antibody That Demonstrates a Favorable Safety Profile and Potent Anti-Tumor Efficacy in Patients with Relapsed/Refractory Lymphoid Malignancies: Preliminary Results from a Phase I Study

Ningjing Lin, Tingting Du, Hui Zhou, Yajun Li, Liang Wang, Xiaomeng Dong, Haochuan Zheng, Jingtao Lu, Mi Tang, Jihua Wu, Wei Zhu, Yuqin Song, Jun Zhu

Blood (2024) 144 (Supplement 1): 4175.

https://doi.org/10.1182/blood-2024-206674

Published: 2024

Journal Articles

Phase 1/2 Studies of DZD8586, a Non-Covalent BBB Penetrant LYN/BTK Dual Inhibitor, in BTK Inhibitor Resistant Chronic Lymphocytic Leukemia (CLL) and Other B-Cell Non-Hodgkin Lymphoma (B-NHL)

Blood (2024) 144 (Supplement 1): 3248.

https://doi.org/10.1182/blood-2024-197877

Published: 2024

Journal Articles

CD93 + Myeloid Cells Suppress T-Cell-Mediated Anti-Tumor Immunity

Hui Yu, Yixin Qian, Weiping Liu, Lan Mi, Yun Huang, Rui Peng, Jiaowu Cao, Dingyao Hu, Jun Zhu, Yuqin Song, Mi Deng

Blood (2024) 144 (Supplement 1): 960.

https://doi.org/10.1182/blood-2024-201309

Published: 2024

Journal Articles

Safety and Preliminary Efficacy of F0002, an Anti-CD30 Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma Previously Treated with Anti-PD-1 or PD-L1 Therapy: Results from F0002-101 Phase 1 Study

Yuqin Song, Qingsong Yin, Zhiming Li, Jingye Meng, Yan Yan, Mengli Zhou, Wenyi Sun, Kezhen Liu, Jun Zhu

Blood (2024) 144 (Supplement 1): 1674.

https://doi.org/10.1182/blood-2024-193938

Published: 2024

Journal Articles

Five-Year Analysis of the POLARIX Study: Prolonged Follow-up Confirms Positive Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) on Outcomes

Blood (2024) 144 (Supplement 1): 469.

https://doi.org/10.1182/blood-2024-197938

Published: 2024

Journal Articles

Study of PC-002 (Sepantronium Bromide), a First-in-Class Inhibitor of Deubiquitinases (DUBs) Targeting Myc Degradation in Relapsed/Refractory c-Myc Rearranged High-Grade B Cell Lymphoma (HGBCL): Updated Phase 2 Results

Blood (2024) 144 (Supplement 1): 3120.

https://doi.org/10.1182/blood-2024-206700

Published: 2024

Journal Articles

Rocbrutinib, a New-Generation BTK Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Non-GCB Diffuse Large B Cell Lymphoma

Blood (2024) 144 (Supplement 1): 3119.

https://doi.org/10.1182/blood-2024-194561

Published: 2024

Journal Articles

Phase Ib/IIa Study of Amulirafusp Alfa (IMM0306) in Combination with Lenalidomide in Patients with Relapsed or Refractory CD20-Positive B-Cell Non-Hodgkin's Lymphoma

Lijuan Deng, Yanyan Liu, Ningjing Lin, Zhihua Yao, Jiuyang Zhang, Wei Meng, Qiying Lu, Wenzhi Tian, Jun Zhu, Yuqin Song

Blood (2024) 144 (Supplement 1): 3033.

https://doi.org/10.1182/blood-2024-200539

Published: 2024

Journal Articles

Time Series Deep Neural Network Identifies Lymphoma Patients Suitable for CAR-T Cell Therapy Using EHR Data

Meihua Long, Fan Jia, Jili Deng, Jianing Zhang, Ziran Zhao, Yan Xie, Lan Mi, Yan Hou, Yuqin Song

Blood (2024) 144 (Supplement 1): 2233.

https://doi.org/10.1182/blood-2024-209699

Published: 2024

Journal Articles

Safety and Efficacy in Patients with Advanced Lymphomas from a Global Phase 1a/1b, First-in-Human Study of CS5001, a Novel Anti-ROR1 ADC

Blood (2024) 144 (Supplement 1): 1739.

https://doi.org/10.1182/blood-2024-192979

Published: 2024

Journal Articles

Updated Results from the Phase 2 Waveline-004 Study of Zilovertamab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Lalita Norasetthada, Joaquin Diaz, Fangfang Lv, Yuqin Song, Seung Tae Lee, Ewa Paszkiewicz-Kozik, Dipenkumar Modi, Armando Santoro, Kumudu Pathiraja, Nishitha Reddy, Rushdia Yusuf, Muhit Ozcan

Blood (2024) 144 (Supplement 1): 1738.

https://doi.org/10.1182/blood-2024-201522

Published: 2024

Journal Articles

Updated Results from a Multicenter, Phase II Study of Zanubrutinib in Combination with Rituximab and Methotrexate, Followed By Zanubrutinib Maintenance in Patients with Secondary Central Nervous System Lymphoma

Lijuan Deng, Tianheng He, Yongjing Tang, Lan Mi, Changyu Lu, Hanxiao Liu, Shupeng Zhong, Jin Chai, Jun Luo, Liling Zhang, Shujuan Wen, Xiaopei Wang, Jun Zhu, Yuqin Song

Blood (2024) 144 (Supplement 1): 1735.

https://doi.org/10.1182/blood-2024-209021

Published: 2024

NARROW

Preclinical and First-in-Human Phase I Study of Bruton Tyrosine Kinase Degrader HZ-Q1070 in Patients with Recurrent or Refractory B-Cell Malignancies

Safety and Efficacy of Rocbrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma

SKYGLO: A Global Phase III Randomized Study Evaluating Glofitamab Plus Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Pola-R-CHP in Previously Untreated Patients with Large B-Cell Lymphoma (LBCL)

Molecular Biology Study of Primary Immuno-Privileged Lymphomas

Prognosis Prediction and Treatment Recommendation for Follicular Lymphoma: Enhancing Decision-Making

Linperlisib Combined with CHOP Regimen Followed By Autologous Hematopoietic Stem Cell Transplantation and Linperlisib Monotherapy Maintenance for Newly Diagnosed Nodal T-Follicular Helper Cell Lymphoma Patients: A Phase II Trial

Safety and Efficacy of Iruplinalkib for Patients with Relapsed or Refractory (r/r) ALK+ Lymphoma: A Phase II Trial

MBS303, a Novel 2:1 CD20×CD3 Bispecific Antibody, Demonstrated a Favorable Safety and Potent Antitumor Activity in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma: Preliminary Results from a Phase Ⅰ, Dose-Escalation Trial

BR105 Is a Novel Anti-Sirpα Monoclonal Antibody That Demonstrates a Favorable Safety Profile and Potent Anti-Tumor Efficacy in Patients with Relapsed/Refractory Lymphoid Malignancies: Preliminary Results from a Phase I Study

Phase 1/2 Studies of DZD8586, a Non-Covalent BBB Penetrant LYN/BTK Dual Inhibitor, in BTK Inhibitor Resistant Chronic Lymphocytic Leukemia (CLL) and Other B-Cell Non-Hodgkin Lymphoma (B-NHL)

CD93 + Myeloid Cells Suppress T-Cell-Mediated Anti-Tumor Immunity

Safety and Preliminary Efficacy of F0002, an Anti-CD30 Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma Previously Treated with Anti-PD-1 or PD-L1 Therapy: Results from F0002-101 Phase 1 Study

Five-Year Analysis of the POLARIX Study: Prolonged Follow-up Confirms Positive Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) on Outcomes

Study of PC-002 (Sepantronium Bromide), a First-in-Class Inhibitor of Deubiquitinases (DUBs) Targeting Myc Degradation in Relapsed/Refractory c-Myc Rearranged High-Grade B Cell Lymphoma (HGBCL): Updated Phase 2 Results

Rocbrutinib, a New-Generation BTK Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Non-GCB Diffuse Large B Cell Lymphoma

Phase Ib/IIa Study of Amulirafusp Alfa (IMM0306) in Combination with Lenalidomide in Patients with Relapsed or Refractory CD20-Positive B-Cell Non-Hodgkin's Lymphoma

Time Series Deep Neural Network Identifies Lymphoma Patients Suitable for CAR-T Cell Therapy Using EHR Data

Safety and Efficacy in Patients with Advanced Lymphomas from a Global Phase 1a/1b, First-in-Human Study of CS5001, a Novel Anti-ROR1 ADC

Updated Results from the Phase 2 Waveline-004 Study of Zilovertamab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Updated Results from a Multicenter, Phase II Study of Zanubrutinib in Combination with Rituximab and Methotrexate, Followed By Zanubrutinib Maintenance in Patients with Secondary Central Nervous System Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only